OncLive TV

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the importance of understanding patient preferences regarding treatment regimens.

Derek Sant'Angelo, PhD, Division Chief, Developmental Biology, Robert Wood Johnson Medical School, Dept. of Pediatrics, discusses what medical oncologists need to understand about immunology.

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses how personalized medicine may eventually help with preventing cancer.

Ursula A. Matulonis, MD, medical director, gynecologic oncology, Susan F. Smith Center for Women's Cancers, institute physician, Dana-Farber Cancer Institute, discusses managing toxicities associated with olaparib for patients with ovarian cancer.

Richard D. Carvajal, MD, Director, Experimental Therapeutics and Melanoma Service New York-Presbyterian Hospital/ Columbia University Medical Center, discusses the challenge of using vaccines for cancer therapy.

Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.

Tracey L. Evans, MD, associate professor of clinical medicine, University of Pennsylvania Health System, discusses treatment of poor performance status (PS) and elderly patients with lung cancer.

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.

Loren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Rutgers Cancer Institute of New Jersey, discusses the use of oncolytic viruses for the treatment of advanced melanoma.

Brian Van Tine, MD, PhD, assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses sequencing in gastrointestinal stromal tumors (GIST).

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, discusses increasing cause of hepatocellular carcinoma (HCC) and unmet needs related to the disease.

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Former ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.